Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced that several of its drugs have been included in the National Reimbursement Drug List (NRDL) in China. This inclusion, facilitated through negotiations, marks a significant milestone for the company, potentially enhancing its market presence and accessibility of its drugs to a broader patient base. The inclusion of these drugs in the NRDL is expected to positively impact the company’s operations and strengthen its position in the pharmaceutical industry.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$86.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of innovative drugs. The company operates in the healthcare industry, offering a range of pharmaceutical products, including cancer treatments and other specialized medications.
Average Trading Volume: 3,990,010
Technical Sentiment Signal: Hold
Current Market Cap: HK$449.1B
Find detailed analytics on 1276 stock on TipRanks’ Stock Analysis page.